AbbVie Gets FDA Expanded Nod for Rinvoq in Crohn's Disease
May 18 2023 - 1:55PM
Dow Jones News
By Colin Kellaher
AbbVie on Thursday said the Food and Drug Administration has
approved the expanded use of its blockbuster immunology drug Rinvoq
for adults with moderately to severely active Crohn's disease.
The North Chicago, Ill., company said the approval covers Rinvoq
as a once-daily pill for adults with the chronic inflammatory bowel
disorder who have had an inadequate response or intolerance to one
or more TNF blockers and marks the seventh FDA nod for the drug
across rheumatology, dermatology and gastroenterology.
AbbVie is counting on Rinvoq and its blockbuster psoriasis drug
Skyrizi to help make for lost sales for its mega-blockbuster
Humira, the highest-grossing drug of all time, which faces new
competition from copycats after patent expirations.
AbbVie is targeting combined 2025 risk-adjusted sales for Rinvoq
and Skyrizi of more than $17.5 billion and combined peak sales for
the two drugs topping $21 billion in 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 18, 2023 13:40 ET (17:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024